Business
BioVie Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at ATMRD 2024
SUNRISE-PD to evaluate the effect of bezisterim (NE3107) on motor and non-motor symptoms in ~60 patients with Parkinson’s disease who are naïve to
About this update from Biovie Inc.
[{"type":"text","content":"SUNRISE-PD to evaluate the effect of bezisterim (NE3107) on motor and non-motor symptoms in ~60 patients with Parkinson’s disease who are naïve to carbidopa/levodopa Additional presentation at congress highlighted data from earlier Phase 2a trial of bezisterim in Parkinson’s disease that helped inform SUNRISE-PD trial design CARSON CITY, Nev., June 25, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced data from two presentations at the Advanced Therapeutics in Movement and Related Disorders Congress® (ATMRD Congress) held June 21-25, 2024 in Washington, D.C. Presentations include a first look at the protocol design of the upcoming SUNRISE-PD Phase 2 trial of bezisterim (NE3107) in patients with early Parkinson’s disease along with an encore presentation of detailed results from the Company’s Phase 2a trial of bezisterim adjunctive to carbidopa/levodopa (C/L) in patients with Parkinson’s disease. \"Promising preclinical data suggest bezisterim may address unmet needs in Parkinson's disease. Existing treatments offer variable success, and disease progression leads to worsening motor function, dyskinesias, and significant disability,” said Cuong Do, BioVie’s President and CEO. “Bezisterim's unique mechanism of action – targeting inflammation and insulin resistance – holds promise for mitigating these issues based on data from earlier-phase trials. SUNRISE-PD will allow us to further investigate bezisterim's safety and efficacy in a larger patient population who have minimal prior exposure to levodopa, with the goal of developing a treatment that can significantly improve the lives of people with Parkinson's disease.\" Protocol Design of SUNRISE-PD: A Phase 2, Placebo-Controlled Study of Bezisterim in Early Parkinson’s DiseaseThe presentation Assessment of Bezisterim (NE3107) in Patients with Early Parkinson’s Disease: A Phase 2, Placebo-Controlled Study outlined the study protocol of the Company’s upcoming SUNRISE-PD Phase 2 trial evaluating bezisterim in patients with Parkinson’s disease who have had minimal exposure to C/L treatment but in need of symptomatic therapy for motor symptoms. SUNRISE-PD will be a Phase 2, multicenter, r...